0001213900-24-030829.txt : 20240405 0001213900-24-030829.hdr.sgml : 20240405 20240405161029 ACCESSION NUMBER: 0001213900-24-030829 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240405 DATE AS OF CHANGE: 20240405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Citius Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001506251 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 273425913 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38174 FILM NUMBER: 24826590 BUSINESS ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 BUSINESS PHONE: (908) 967-6676 MAIL ADDRESS: STREET 1: 11 COMMERCE DRIVE STREET 2: 1ST FLOOR CITY: CRANFORD STATE: NJ ZIP: 07016 FORMER COMPANY: FORMER CONFORMED NAME: Trail One, Inc. DATE OF NAME CHANGE: 20110314 FORMER COMPANY: FORMER CONFORMED NAME: TrailOne, Inc. DATE OF NAME CHANGE: 20101119 8-K 1 ea0203367-8k_citius.htm CURRENT REPORT
false 0001506251 0001506251 2024-04-03 2024-04-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) April 3, 2024

 

 

 

Citius Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Nevada

(State or other jurisdiction of incorporation)

 

001-38174

  

27-3425913

(Commission File Number)

   (IRS Employer Identification No.)

 

11 Commerce Drive, 1st Floor, Cranford, NJ

   07016

(Address of principal executive offices)

   (Zip Code)

 

Registrant's telephone number, including area code (908) 967-6677

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class

  

 

Trading Symbol(s)

  

Name of each exchange

on which registered

Common stock, $0.001 par value   CTXR   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On April 3, 2024, the Board of Directors of the Citius Pharmaceuticals, Inc. (the “Company”) approved an extension by one year to April 5, 2025 for warrants to purchase an aggregate of 1,294,498 shares of common stock, $0.001 par value per share, with an exercise price of $1.42 per share of common stock (the “Investor Warrants”). The Investor Warrants are held by Leonard Mazur, the Company’s Chief Executive Officer and Chairman of the Board of Directors, and Myron Holubiak, the Company’s Executive Vice President and member of the Board of Directors, and were originally issued in April 2019 in a private placement conducted simultaneously with a registered direct offering of shares of common stock (the “2019 Offering”) managed by H. C. Wainwright & Co., LLC (“Wainwright”). Mr. Mazur and Mr. Holubiak participated in the private placement on the same basis as all other investors. Additionally, 240,130 warrants with an exercise price of $1.9313 per share (the “Placement Agent Warrants” and together with the Investor Warrants, the “Warrants”) issued in connection with the 2019 Offering were extended by one year to April 5, 2025. Such Placement Agent Warrants are held by certain representatives of Wainwright or their assignees. The terms of the Warrants were previously extended in April 2021 to April 5, 2024. There are no other Warrants remaining outstanding from the 2019 Offering and if such Warrants are fully exercised, the Company would receive approximately $2.3 million in cash proceeds.

 

Except as set forth above, all other terms, conditions and rights of the Warrants remain in full force and effect, which were described in the Current Report on Form 8-K filed by the Company on April 3, 2019 (the “Original Form 8-K”). The foregoing descriptions of the Investor Warrants and the Placement Agent Warrants are not complete and are qualified in their entirety by reference to Exhibits 4.1 and 4.2, respectively, of the Original Form 8-K.

  

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CITIUS PHARMACEUTICALS, INC.
     
Date: April 5, 2024   /s/ Leonard Mazur
    Leonard Mazur
    Chairman and Chief Executive Officer

 

 

2

 

 EX-101.SCH 2 ctxr-20240403.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ctxr-20240403_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 ctxr-20240403_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Apr. 03, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 03, 2024
Entity File Number 001-38174
Entity Registrant Name Citius Pharmaceuticals, Inc.
Entity Central Index Key 0001506251
Entity Tax Identification Number 27-3425913
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 11 Commerce Drive
Entity Address, Address Line Two 1st Floor
Entity Address, City or Town Cranford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07016
City Area Code 908
Local Phone Number 967-6677
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol CTXR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://citiuspharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ctxr-20240403.xsd ctxr-20240403_lab.xml ctxr-20240403_pre.xml ea0203367-8k_citius.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0203367-8k_citius.htm": { "nsprefix": "CTXR", "nsuri": "http://citiuspharma.com/20240403", "dts": { "schema": { "local": [ "ctxr-20240403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ctxr-20240403_lab.xml" ] }, "presentationLink": { "local": [ "ctxr-20240403_pre.xml" ] }, "inline": { "local": [ "ea0203367-8k_citius.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://citiuspharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0203367-8k_citius.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-03", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0203367-8k_citius.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://citiuspharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001213900-24-030829-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-030829-xbrl.zip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

XML 16 ea0203367-8k_citius_htm.xml IDEA: XBRL DOCUMENT 0001506251 2024-04-03 2024-04-03 iso4217:USD shares iso4217:USD shares false 0001506251 8-K 2024-04-03 Citius Pharmaceuticals, Inc. NV 001-38174 27-3425913 11 Commerce Drive 1st Floor Cranford NJ 07016 908 967-6677 false false false false Common stock, $0.001 par value CTXR NASDAQ false